Migraine

>

Latest News

For Patients with Migraine who do Not Initially Respond to CGRP Inhibitor Therapy, Switching mAbs May Provide Relief / image credit courtesy of Fundación Jiménez Díaz University Hospital
Switching Anti-CGRP Monoclonal Antibody Therapy in Nonresponders with Migraine May Reduce Monthly Headache Days

April 29th 2025

Subgroup analyses found no significant difference in efficacy based on change in therapeutic action (ie, CGRP vs its receptor), doses, or intertreatment interval.

FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention
FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention

April 16th 2025

Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents / image credit ©Lightspring/shutterstock.com
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents

February 27th 2025

Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial

February 25th 2025

FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose

February 6th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.